🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT04098146
Recruiting Observational

Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis

NCT04098146 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2022-09-12
Last updated
2025-09-04

Condition(s) studied

Mandibular ReconstructionSegmental Mandibular Defects

Investigational drug(s) / intervention(s)

Surgical Resection and Reconstruction

Surgical Resection and Reconstruction: One stage reconstruction: Osseous reconstruction is performed in the same surgery of the tumor/mandibular resection. It is also known as immediate or primary reconstruction. Second stage reconstruction: Osseous reconstruction is performed after the tumor/mandibular resection surgery as an independent surgery. After the mandibular resection a temporary alloplastic bridging might be put in place. It is also known as delayed or secondary reconstruction.

Study summary

Prospective will be collected in a minimum of 300 patients presenting with an acquired segmental mandibular defect ≥ 2 cm secondary to OSSC removal and drugs-induced osteonecrosis, and who require mandibular reconstruction.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * The study includes patients with an initial pathological/histologic diagnosis of mandibular involvement by oral tumors (such as OSCC, osteosarcoma, and ameloblastoma), bisphosphonate- or immunomodulatory drug-induced osteonecrosis, and mandibular lesions from metastatic conditions originating from other sites including lung, breast, prostate, or kidney. * Age 18 years and older * Bisphosphonate related osteonecrosis of the mandible * Immunomodulatory drugs induced mandibular osteonecrosis * Patients presented with ameloblastoma affecting the mandible * Patients presented with osteosarcomas of the mandible * Patients presented with oral metastases related mandibular lesions that are indicated for segmental resection, common primary tumor sites include lung, breast, prostate and kidney * Undergoing primary curative treatment with segmental resection of the mandible ≥2 cm * Intention to undergo mandibular reconstruction with autologous bone using a primary (one-stage) or secondary (two-stage) approach * Informed consent obtained, ie: * Ability to understand the content of the patient information/ICF * Willingness and ability to participate in the clinical investigation according to the registry plan (RP) o Signed and dated IRB/EC approved ICF OR * Written consent provided according to the IRB/EC defined and approved procedures for patients who are not able to provide to provide independent written informed consent Exclusion Criteria: * Tumors affecting the condyle * Patients under palliative care * Previous extensive mandibular surgeries (including reconstructions, e.g., TMJ replacement) that may potentially confound the outcome measures Intraoperative exclusion criteria: * Nonsegmental mandibular defect (eg. box resection/partial resection) * Segmental mandibular defect of less than 2 cm * Mandibular defects extending beyond the sigmoid notch into the condyles Additional exclusion criterion: • No osseous reconstruction with autologous bone performed within 18 months from resection

Primary outcome measure(s)

Trial sites (19)

FacilityCityRegionStatus
University of Florida College of Medicine Jacksonville Florida Recruiting
University of Illinois Chicago Chicago Illinois Recruiting
Northwell Health Cancer Institute New Hyde Park New York Not Yet Recruiting
Mount Sinai Hospital New York New York Recruiting
John Peter Smith Health Network Fort Worth Texas Recruiting
Universitätsklinikum Tübingen Tübingen Baden-Wurttemberg Recruiting
University Hospital RWTH Aachen Aachen Germany Recruiting
University Hospital Charité Berlin Germany Recruiting
Hannover Medical School Hanover Germany Recruiting
Universitätsklinikum Heidelberg Heidelberg Germany Recruiting
University Hospital Leipzig Leipzig Germany Recruiting
Klinikum der LMU München Munich Germany Recruiting
University Hospital Ulm Ulm Germany Recruiting
Shimane University Izumo Japan Not Yet Recruiting
Erasmus University Medical Centre Rotterdam Netherlands Recruiting
Luz Hospital Lisbon Portugal Not Yet Recruiting
12 de Octubre Madrid Spain Recruiting
Uppsala University Hospital Uppsala Sweden Recruiting
University Hospital Basel Basel Switzerland Recruiting

More AO Innovation Translation Center trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04098146 on ClinicalTrials.gov ↗ ← All trials in Germany